# Melanotan II: Research Overview — Peptides Emporium > A literature summary of Melanotan II (MT-2), a cyclic alpha-MSH analog studied for skin pigmentation and erectile function. Covers MC1R-cAMP-MITF mechanism, Phase I data, documented safety risks and regulatory status. A cyclic melanocortin peptide that drives pigmentation and erection through non-selective receptor agonism — two small Phase I studies, no approvals, and a documented pattern of adverse events. ## The short version Melanotan II (also written Melanotan 2, MT-2, or MTII) is a synthetic cyclic peptide modeled on part of a naturally occurring tanning hormone called alpha-MSH (alpha-melanocyte-stimulating hormone). Researchers at the University of Arizona designed it in the late 1980s to be a more potent, more stable version of that hormone, able to trigger skin darkening at lower amounts and without breaking down as fast. In early human studies it did tan skin and it did cause erections — both through its action on receptors in the brain and skin [5][6]. But development never reached large trials. Today Melanotan II is handled as a research chemical only. It is **not approved by the FDA, EMA, TGA, MHRA, or any other regulator for any use**. It is distinct from two other melanocortin drugs: afamelanotide (a separate linear analog studied for a rare light-sensitivity disease) and bremelanotide (a shorter analog studied for sexual desire disorder) — neither approval covers Melanotan II. It is prohibited in sport. And it carries a real and documented list of harms — darkening of existing moles, new moles appearing, kidney and muscle injury, priapism, and the persistent problem of contaminated unregulated product — that this page covers without minimizing [3]. ## What it is Melanotan II is a heptapeptide (seven amino acids) with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2. The cyclic (ring-closed, lactam-bridged) structure and the D-amino acid substitution make it more resistant to breakdown and more potent than the parent hormone. Molecular formula C50H69N15O9. Its synonyms include MT-II, MTII, Melanotan 2, and — in anti-doping and forensic work — by that chemical sequence. It belongs to the melanocortin family: peptides that act at the five human melanocortin receptors (MC1R through MC5R). Melanotan II is non-selective — it engages all five, which is why its effects reach beyond skin into appetite, sexual function and cardiovascular tone. It should not be confused with afamelanotide (sometimes called Melanotan I), which is a separate, linear analog that has been approved for a rare disease called erythropoietic protoporphyria, nor with bremelanotide (derived from Melanotan II but further modified), which has a separate approval for hypoactive sexual desire disorder in premenopausal women. Those approvals and their safety data do not extend to Melanotan II [4]. ## How it works The pigmentation mechanism runs through MC1R. When Melanotan II binds MC1R on melanocytes (the skin's pigment cells), it raises intracellular cAMP, which activates protein kinase A (PKA), which phosphorylates CREB, which upregulates MITF — the master transcription factor for melanogenesis. MITF turns on tyrosinase and the enzymes downstream of it, shifting production from the lighter pigment pheomelanin toward the darker eumelanin. The result is a darker skin color, and unlike UV-induced tanning it does not require sun exposure to trigger the cascade [6]. The erection effect runs through a different receptor. MC4R (and to a degree MC3R) activation in the hypothalamus and mesolimbic system drives pro-erectile signaling via pathways distinct from the skin pathway. In a controlled crossover study in ten men with psychogenic erectile dysfunction, a single subcutaneous dose produced erections in eight of ten subjects [5]. The appetite effect — reduced food intake — comes from MC4R and MC3R activation in the nucleus accumbens, as shown in mouse microinjection work where Melanotan II directly into that brain region decreased both eating and the motivation to seek food, without causing conditioned aversion [2]. Because it is non-selective, all five receptor types are activated to varying degrees, which is also the source of its side-effect breadth: MC5R activity in exocrine and sebaceous glands, cardiovascular MC3R/MC4R effects on blood pressure, and so on. ## What the research shows *Phase I tanning and pigmentation.* In a single-blind alternating-day pilot in three healthy male volunteers, subcutaneous Melanotan II (escalated from 0.01 to 0.025-0.03 mg/kg, given on alternating weekdays for two weeks) increased facial, upper-body and buttock pigmentation in two of three subjects after only five low doses — without any UV exposure. Spontaneous penile erections lasting one to five hours were reported, along with mild nausea, and dose-limiting somnolence appeared at 0.03 mg/kg [6]. This was published in 1996 and remains one of the most-cited MT-II clinical observations. *Phase I erectile dysfunction.* A double-blind, placebo-controlled crossover study in ten men with psychogenic erectile dysfunction found that a single subcutaneous dose produced clinically apparent erections in eight of ten; mean duration of greater than 80% tip rigidity was 38.0 minutes versus 3.0 minutes for placebo (p=0.0045). Transient nausea, stretching and yawning required no treatment [5]. This is the strongest controlled human efficacy signal in the MT-II record. *Oral mucosal pigmentation (2026).* A case report documents a man who self-administered Melanotan II over 64 days; he developed brown pigmentation on the attached gingiva of both jaws and on the buccal mucosa, with buccal pigmentation beginning to fade by 28 days after stopping while gingival pigmentation persisted at reduced intensity at three months [1]. *Mesolimbic appetite suppression.* Bilateral microinjection of Melanotan II into the nucleus accumbens of male mice significantly decreased food consumption across both free-feeding and operant paradigms without producing conditioned taste aversion or changing metabolic rate — a mechanistically precise demonstration that central melanocortin signaling in this region drives appetite reduction independently of metabolic effects [2]. *Historical and development lineage.* A 2006 review traces the research pathway from linear Melanotan I (tanning) through cyclic Melanotan II (erections) to the shorter bremelanotide analog (sexual dysfunction), documents the receptor basis of their different profiles, and establishes MT-II as the non-selective ancestor whose activity map explains both what its successors do and what it does itself [4]. *Social media and public-health framing.* A 2025 analysis examined how Melanotan is marketed and perceived online — the so-called "Barbie drug" framing — and documented the gap between social-media promotion and the compound's documented safety risks as an unlicensed product [7]. ## Reported effects, cautions & safety **Community-reported effects (anecdotal, not clinical evidence):** The following are drawn from published qualitative analyses of user forums and harm-reduction commentary — not from controlled trials. They are compiled here because they are part of the documented real-world experience of people who have used this compound, and omitting them would be a gap in the record. They are **not** an endorsement of use. Users most commonly report: a rapid, deep tan with little sun exposure; dramatically reduced appetite, often from the first dose; strong and sometimes sudden surges in libido and spontaneous erections (men); nausea — very commonly, peaking in the first hours after a dose and easing somewhat over time; facial flushing; a distinctive and frequently mentioned urge to stretch and yawn after injecting; darkening of existing moles and freckles, often before the general tan develops; appearance of new moles; darkening of lips, gums, scars and genital skin; and fatigue or a flu-like tiredness in early use (sometimes called "melanotan flu"). The tan itself is widely described as uneven, blotchy, or unnaturally long-lasting, and as fading patchily over weeks to months after stopping. **Cited safety cautions (from the published literature):** - *New, changing, or darkening moles and melanoma risk.* As a non-selective MC1R agonist, Melanotan II drives melanocyte activity throughout the skin. Multiple case reports document eruptive new nevi, dysplastic (atypical) nevi, and darkening of existing moles. Further reports document melanoma and melanoma in situ in melanotan users, and dermoscopy studies show measurable melanocytic lesion changes during use. Any new or changing mole during or after use warrants prompt dermatological assessment. - *Rhabdomyolysis and acute kidney injury.* A case report and literature review linked Melanotan II injection to renal infarction — a blockage of blood supply to the kidney — with the authors noting prior reports of rhabdomyolysis (severe muscle breakdown) and renal failure, and proposing thrombotic and direct-toxic renal mechanisms [3]. - *Priapism.* Because melanocortin agonism promotes erections, case reports describe priapism — a prolonged, painful erection — following tanning injections, including after apparent overdose. Priapism is a urological emergency that can cause permanent tissue damage. - *Posterior reversible encephalopathy syndrome (PRES).* A case report describes PRES — a neurological condition involving brain swelling, with headache, seizures, visual disturbance and high blood pressure — in association with melanotan use, consistent with the compound's effects on vascular tone. - *Nausea and cardiovascular / blood-pressure effects.* Preclinical hemodynamic work shows melanocortin agonists can raise blood pressure, an effect worsened by impaired nitric oxide signaling. Combined with the very commonly reported nausea, this points to meaningful cardiovascular and gastrointestinal effects that are poorly characterized in humans using unregulated product. - *Unregulated product risk.* Analytical studies of melanotan products bought online repeatedly find inaccurate labeling, variable peptide content, and impurities. A buyer cannot know the actual identity, dose, purity or sterility of what is in the vial — which compounds every other risk. - *No approval; unknown long-term safety.* Melanotan II has never been approved anywhere for any use. Development did not progress through late-phase trials, so its long-term human safety is unknown. WADA lists it under the S0 (Non-Approved Substances) category — prohibited in sport at all times. ## Where it fits in skin research Among the two peptides on this desk, Melanotan II is the lead — and the one with the sharpest profile. It is the best evidence that melanocortin receptor agonism can produce measurable pigmentation in humans without UV [6], and the two small Phase I studies are genuinely informative about what it does. But it is also the compound on this desk with the longest list of documented adverse events, no regulatory approval anywhere, and a widespread black-market supply that introduces its own layer of hazard. Read alongside [GHK-Cu](/ghk-cu) — which rebuilds the collagen matrix underneath the skin's surface rather than re-pigmenting it — Melanotan II illustrates the contrast between an acute, receptor-mediated signal and a slower, scaffolding-level repair process. See how they compare on the [comparison page](/compare). ![Melanotan II research illustration — cyclic heptapeptide and melanin synthesis cascade](/images/melanotan-2.webp) --- Peer-reviewed literature on two skin peptides. Not a clinic, not a vendor, not a dose.